| Pharmaceutical Information |
| Drug Name |
Lomustine |
| Drug ID |
BADD_D01313 |
| Description |
An alkylating agent of value against both hematologic malignancies and solid tumors. |
| Indications and Usage |
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01AD02 |
| DrugBank ID |
DB01206
|
| KEGG ID |
D00363
|
| MeSH ID |
D008130
|
| PubChem ID |
3950
|
| TTD Drug ID |
D04JPJ
|
| NDC Product Code |
55111-965; 58181-3041; 58181-3040; 58181-3042; 71052-171 |
| UNII |
7BRF0Z81KG
|
| Synonyms |
Lomustine | NSC-79037 | NSC 79037 | NSC79037 | Cecenu | CeeNU | Belustine | CCNU |
|
| Chemical Information |
| Molecular Formula |
C9H16ClN3O2 |
| CAS Registry Number |
13010-47-4 |
| SMILES |
C1CCC(CC1)NC(=O)N(CCCl)N=O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
